Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 1
2010 1
2011 1
2013 1
2017 1
2018 1
2020 1
2021 4
2022 6
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.
Hashimoto K, Yasumatsu R, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T. Hashimoto K, et al. Among authors: yamauchi m. Anticancer Res. 2022 Feb;42(2):981-989. doi: 10.21873/anticanres.15558. Anticancer Res. 2022. PMID: 35093898
Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.
Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T. Nakano T, et al. Among authors: yamauchi m. In Vivo. 2022 Mar-Apr;36(2):979-984. doi: 10.21873/invivo.12790. In Vivo. 2022. PMID: 35241559 Free PMC article.
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.
Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Taura M, Takeuchi T, Nakagawa T. Nakano T, et al. Among authors: yamauchi m. Anticancer Res. 2022 Jul;42(7):3653-3664. doi: 10.21873/anticanres.15854. Anticancer Res. 2022. PMID: 35790253
Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
Wakasaki T, Manako T, Yasumatsu R, Hara H, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Nishimura E, Takeuchi T, Matsuo M, Jiromaru R, Hashimoto K, Komune N, Nakagawa T. Wakasaki T, et al. Among authors: yamauchi m. PLoS One. 2022 Jul 28;17(7):e0271907. doi: 10.1371/journal.pone.0271907. eCollection 2022. PLoS One. 2022. PMID: 35901098 Free PMC article.
Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.
Yasumatsu R, Shimizu Y, Hanai N, Kariya S, Yokota T, Fujii T, Tsukahara K, Ando M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Nekado T, Yamada T, Homma A. Yasumatsu R, et al. Among authors: yamauchi m. Int J Clin Oncol. 2022 Jan;27(1):95-104. doi: 10.1007/s10147-021-02047-y. Epub 2021 Nov 13. Int J Clin Oncol. 2022. PMID: 34773525 Free PMC article.
25 results